Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,913
  • Shares Outstanding, K 11,495
  • Annual Sales, $ 500 K
  • Annual Income, $ -25,870 K
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 2
  • High Estimate -0.53
  • Low Estimate -0.67
  • Prior Year -2.90
  • Growth Rate Est. (year over year) +79.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.62 +58.01%
on 02/28/19
7.85 -7.01%
on 03/21/19
+2.40 (+48.98%)
since 02/22/19
3-Month
3.60 +102.78%
on 12/27/18
7.85 -7.01%
on 03/21/19
+2.80 (+62.22%)
since 12/21/18
52-Week
3.60 +102.78%
on 12/27/18
20.40 -64.22%
on 03/23/18
-13.00 (-64.04%)
since 03/22/18

Most Recent Stories

More News
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

CARB : 24.40 (-1.49%)
EYES : 0.85 (+2.13%)
LGND : 124.86 (-3.34%)
CATB : 7.30 (-2.14%)
KEG : 4.79 (-17.41%)
Rising P/E an Overlooked Criterion: 5 Top Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.

CARB : 24.40 (-1.49%)
EYES : 0.85 (+2.13%)
LGND : 124.86 (-3.34%)
CATB : 7.30 (-2.14%)
KEG : 4.79 (-17.41%)
Catabasis (CATB) Beats Earnings in Q4, Revenues Nil

Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.

CATB : 7.30 (-2.14%)
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31,...

CATB : 7.30 (-2.14%)
Catabasis Pharmaceuticals to Present at Oppenheimer's 29th Annual Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate...

CATB : 7.30 (-2.14%)
Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards?

Townsquare's (TSQ) fourth-quarter 2018 results are expected to benefit from higher political revenues.

TSQ : 5.74 (-0.35%)
CATB : 7.30 (-2.14%)
CAG : 26.45 (+2.44%)
AZUL : 30.24 (-6.35%)
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?

During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.

CARA : 18.30 (-6.82%)
CATB : 7.30 (-2.14%)
TLRY : 67.16 (-4.40%)
ATHX : 1.52 (-6.17%)
Is a Beat in Store for Catabasis (CATB) This Earnings Season?

Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

CARA : 18.30 (-6.82%)
CATB : 7.30 (-2.14%)
TLRY : 67.16 (-4.40%)
NVAX : 0.54 (-13.44%)
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2018 financial results before the Nasdaq Global...

CATB : 7.30 (-2.14%)
Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

CAMBRIDGE, Massachusetts, Feb. 19 -- Catabasis Pharmaceuticals, Inc issued the following news release:

CATB : 7.30 (-2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 7.83
1st Resistance Point 7.56
Last Price 7.30
1st Support Level 7.10
2nd Support Level 6.91

See More

52-Week High 20.40
Fibonacci 61.8% 13.98
Fibonacci 50% 12.00
Fibonacci 38.2% 10.02
Last Price 7.30
52-Week Low 3.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar